메뉴 건너뛰기




Volumn 15, Issue 4, 2015, Pages 529-546

Glycoconjugate vaccines: An update

Author keywords

Glycoconjugate vaccines; Haemophilus influenzae type b; Meningococcus; Pneumococcus; Vaccine use

Indexed keywords

BACTERIAL VACCINE; GLYCOCONJUGATE; MEN C GLYCOCONJUGATE VACCINE; MENACWY CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; SEROGROUP A MENINGOCOCCAL CONJUGATE VACCINE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; VACCINE;

EID: 84925251152     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.993375     Document Type: Article
Times cited : (65)

References (162)
  • 1
    • 69949109911 scopus 로고    scopus 로고
    • Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: Global estimates
    • Watt JP, Wolfson LJ, O'Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009;374:903-11
    • (2009) Lancet , vol.374 , pp. 903-911
    • Watt, J.P.1    Wolfson, L.J.2    O'Brien, K.L.3
  • 2
    • 77952224999 scopus 로고    scopus 로고
    • Accessed 20 August 2014
    • World Health Organization. Global Immunization Data. 2014. Available from: http://www.who. int/immunization/monitoring-surveillance/Global-Immunization-Data.pdf [Accessed 20 August 2014]
    • (2014) Global Immunization Data
    • World Health Organization1
  • 4
    • 80555156134 scopus 로고    scopus 로고
    • Neisseria meningitidis: Biology, microbiology, and epidemiology
    • Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol 2012;799:1-20
    • (2012) Methods Mol Biol , vol.799 , pp. 1-20
    • Rouphael, N.G.1    Stephens, D.S.2
  • 5
    • 67349267346 scopus 로고    scopus 로고
    • Global epidemiology of meningococcal disease
    • Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27(Suppl 2):B51-63
    • (2009) Vaccine , vol.27 , pp. B51-B63
    • Harrison, L.H.1    Trotter, C.L.2    Ramsay, M.E.3
  • 6
    • 85081860442 scopus 로고    scopus 로고
    • Meningococcal disease in countries of the African meningitis belt, 2012
    • Accessed 21 August 2014
    • World Health Organization. Meningococcal disease in countries of the African meningitis belt, 2012 - emerging needs and future perspectives. 2013. Available from: http://www.who.int/wer/2013/wer8812.pdf [Accessed 21 August 2014]
    • (2013) Emerging Needs and Future Perspectives
    • World Health Organization1
  • 9
    • 79954645991 scopus 로고    scopus 로고
    • Healthcare utilization and cost of pneumococcal disease in the United States
    • Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011;29:3398-412
    • (2011) Vaccine , vol.29 , pp. 3398-3412
    • Huang, S.S.1    Johnson, K.M.2    Ray, G.T.3
  • 10
    • 79952498476 scopus 로고    scopus 로고
    • Meningococcal glycoconjugate vaccines
    • Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin 2011;7:170-82
    • (2011) Hum Vaccin , vol.7 , pp. 170-182
    • Gasparini, R.1    Panatto, D.2
  • 11
    • 33846071231 scopus 로고    scopus 로고
    • Conquering the meningococcus
    • Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007;31:3-14
    • (2007) FEMS Microbiol Rev , vol.31 , pp. 3-14
    • Stephens, D.S.1
  • 12
    • 0031954454 scopus 로고    scopus 로고
    • Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994
    • Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998;26:1159-64
    • (1998) Clin Infect Dis , vol.26 , pp. 1159-1164
    • Erickson, L.1    De Wals, P.2
  • 13
    • 27844551865 scopus 로고    scopus 로고
    • Prevention of meningococcal disease
    • Kimmel SR. Prevention of meningococcal disease. Am Fam Physician 2005;72:2049-56
    • (2005) Am Fam Physician , vol.72 , pp. 2049-2056
    • Kimmel, S.R.1
  • 14
    • 84870863719 scopus 로고    scopus 로고
    • Glycoconjugate vaccines
    • Pace D. Glycoconjugate vaccines. Expert Opin Biol Ther 2013;13(1):11-33
    • (2013) Expert Opin Biol Ther , vol.13 , Issue.1 , pp. 11-33
    • Pace, D.1
  • 15
    • 84892730857 scopus 로고    scopus 로고
    • Effect of a serogroup A meningococcal conjugate vaccine (PsATT) on serogroup A meningococcal meningitis and carriage in Chad: A community study
    • Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsATT) on serogroup A meningococcal meningitis and carriage in Chad: a community study Lancet. 2014;383:40-7
    • (2014) Lancet. , vol.383 , pp. 40-47
    • Daugla, D.M.1    Gami, J.P.2    Gamougam, K.3
  • 16
    • 0029653518 scopus 로고
    • Whole-genome random sequencing and assembly of Haemophilus influenzae Rd
    • Fleischmann RD, Adams MD, White O, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995;269:496-512
    • (1995) Science , vol.269 , pp. 496-512
    • Fleischmann, R.D.1    Adams, M.D.2    White, O.3
  • 18
    • 77957346208 scopus 로고    scopus 로고
    • Global use of Haemophilus influenzae type b conjugate vaccine
    • Ojo LR, O'Loughlin RE, Cohen AL, et al. Global use of Haemophilus influenzae type b conjugate vaccine. Vaccine 2010;28:7117-22
    • (2010) Vaccine , vol.28 , pp. 7117-7122
    • Ojo, L.R.1    O'Loughlin, R.E.2    Cohen, A.L.3
  • 19
    • 0025321343 scopus 로고
    • Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine
    • Shapiro ED, Berg AT. Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine. Pediatrics 1990;85:643-7
    • (1990) Pediatrics , vol.85 , pp. 643-647
    • Shapiro, E.D.1    Berg, A.T.2
  • 20
    • 84890047355 scopus 로고    scopus 로고
    • Invasive Haemophilus influenzae type b disease in England and Wales: Who is at risk after 2 decades of routine childhood vaccination?
    • Collins S, Ramsay M, Campbell H, et al. Invasive Haemophilus influenzae type b disease in England and Wales: who is at risk after 2 decades of routine childhood vaccination? Clin Infect Dis 2013;57:1715-21
    • (2013) Clin Infect Dis , vol.57 , pp. 1715-1721
    • Collins, S.1    Ramsay, M.2    Campbell, H.3
  • 21
    • 77949327232 scopus 로고    scopus 로고
    • Immunogenicity of Haemophilus influenzae Type b Conjugate Vaccines in Korean infants:A meta-analysis
    • Hyunju L, Seokyung H, Lee HJ, Kim KH. Immunogenicity of Haemophilus influenzae Type b Conjugate Vaccines in Korean infants:a meta-analysis. J Korean Med Sci 2010;25(1):90-6
    • (2010) J Korean Med Sci , vol.25 , Issue.1 , pp. 90-96
    • Hyunju, L.1    Seokyung, H.2    Lee, H.J.3    Kim, K.H.4
  • 22
    • 33745322043 scopus 로고
    • Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era
    • Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6
    • (1993) JAMA , vol.269 , pp. 221-226
    • Adams, W.G.1    Deaver, K.A.2    Cochi, S.L.3
  • 24
    • 84881473631 scopus 로고    scopus 로고
    • Impact of Haemophilus influenzae type b vaccination on the incidence of invasive Haemophilus influenzae disease in France, 15 years after its introduction
    • Georges S, Lepoutre A, Dabernat H, Levy-Bruhl D. Impact of Haemophilus influenzae type b vaccination on the incidence of invasive Haemophilus influenzae disease in France, 15 years after its introduction. Epidemiol Infect 2013;141:1787-96
    • (2013) Epidemiol Infect , vol.141 , pp. 1787-1796
    • Georges, S.1    Lepoutre, A.2    Dabernat, H.3    Levy-Bruhl, D.4
  • 25
    • 85081870420 scopus 로고    scopus 로고
    • http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HaemophilusInfluenzaeTypeB/EpidemiologicalData/ [Accessed 4 September 2014]
    • Public Health England. Haemophilus influenzae Epidemiological Data. Available from: http://webarchive. nationalarchives.gov.uk/20140714084352/http://www.hpa.org. uk/Topics/InfectiousDiseases/InfectionsAZ/HaemophilusInfluenzaeTypeB/EpidemiologicalData/[Accessed 4 September 2014]
    • Haemophilus Influenzae Epidemiological Data
    • Public Health England1
  • 26
    • 80355141578 scopus 로고    scopus 로고
    • Haemophilus influenzae infections in the H. Influenzae type b conjugate vaccine era
    • Agrawal A, Murphy TF. Haemophilus influenzae infections in the H. influenzae type b conjugate vaccine era. J Clin Microbiol 2011;49:3728-32
    • (2011) J Clin Microbiol , vol.49 , pp. 3728-3732
    • Agrawal, A.1    Murphy, T.F.2
  • 27
    • 0031457271 scopus 로고    scopus 로고
    • Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T
    • Heath PT, Bowen-Morris J, Griffiths D, et al. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child 1997;77:488-92
    • (1997) Arch Dis Child , vol.77 , pp. 488-492
    • Heath, P.T.1    Bowen-Morris, J.2    Griffiths, D.3
  • 28
    • 67651087009 scopus 로고    scopus 로고
    • Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom
    • Ladhani S, Heath PT, Ramsay ME, et al. Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis 2009;49:372-80
    • (2009) Clin Infect Dis , vol.49 , pp. 372-380
    • Ladhani, S.1    Heath, P.T.2    Ramsay, M.E.3
  • 29
    • 84856698739 scopus 로고    scopus 로고
    • Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom
    • Ladhani SN. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Clin Ther 2012;34:385-99
    • (2012) Clin Ther , vol.34 , pp. 385-399
    • Ladhani, S.N.1
  • 30
    • 0038752646 scopus 로고    scopus 로고
    • Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis
    • McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003;361:1521-3
    • (2003) Lancet , vol.361 , pp. 1521-1523
    • McVernon, J.1    Andrews, N.2    Slack, M.P.3    Ramsay, M.E.4
  • 31
    • 59649101899 scopus 로고    scopus 로고
    • Invasive Haemophilus influenzae type B disease in five young children-Minnesota, 2008
    • Centers for Disease Control and Prevention. Invasive Haemophilus influenzae Type B disease in five young children-Minnesota, 2008. MMWR Morb Mortal Wkly Rep 2009;58(3):58-60
    • (2009) MMWR Morb Mortal Wkly Rep , vol.58 , Issue.3 , pp. 58-60
    • Centers for Disease Control and Prevention1
  • 32
    • 4644253794 scopus 로고    scopus 로고
    • Trends in Haemophilus influenzae type b infections in adults in England and Wales: Surveillance study
    • McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 2004;329:655-8
    • (2004) BMJ , vol.329 , pp. 655-658
    • McVernon, J.1    Trotter, C.L.2    Slack, M.P.3    Ramsay, M.E.4
  • 33
    • 0020056871 scopus 로고
    • Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B
    • Insel RA, Anderson PW. Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B. J Immunol 1982;128:1267-70
    • (1982) J Immunol , vol.128 , pp. 1267-1270
    • Insel, R.A.1    Anderson, P.W.2
  • 34
    • 84860319956 scopus 로고    scopus 로고
    • Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era
    • Nix EB, Hawdon N, Gravelle S, et al. Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era. Clin Vaccine Immunol 2012;19:766-71
    • (2012) Clin Vaccine Immunol , vol.19 , pp. 766-771
    • Nix, E.B.1    Hawdon, N.2    Gravelle, S.3
  • 35
    • 77952584729 scopus 로고    scopus 로고
    • Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: Evidence for herd effects and strain replacement due to Hib vaccination
    • Adam HJ, Richardson SE, Jamieson FB, et al. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 2010;28:4073-8
    • (2010) Vaccine , vol.28 , pp. 4073-4078
    • Adam, H.J.1    Richardson, S.E.2    Jamieson, F.B.3
  • 36
    • 84880913322 scopus 로고    scopus 로고
    • Identification of Haemophilus influenzae clones associated with invasive disease a decade after introduction of H. Influenzae serotype b vaccination in Italy
    • Giufrè M, Cardines R, Accogli M, et al. Identification of Haemophilus influenzae clones associated with invasive disease a decade after introduction of H. influenzae serotype b vaccination in Italy. Clin Vaccine Immunol 2013;20:1223-9
    • (2013) Clin Vaccine Immunol , vol.20 , pp. 1223-1229
    • Giufrè, M.1    Cardines, R.2    Accogli, M.3
  • 37
    • 77649108075 scopus 로고    scopus 로고
    • Invasive Haemophilus influenzae Disease, Europe, 1996-2006
    • Ladhani S, Slack MP, Heath PT, et al. Invasive Haemophilus influenzae Disease, Europe, 1996-2006. Emerg Infect Dis 2010;16:455-63
    • (2010) Emerg Infect Dis , vol.16 , pp. 455-463
    • Ladhani, S.1    Slack, M.P.2    Heath, P.T.3
  • 38
    • 84878001032 scopus 로고    scopus 로고
    • Haemophilus influenzae serotype a invasive disease, Alaska, USA, 1983-2011
    • Bruce MG, Zulz T, DeByle C, et al. Haemophilus influenzae serotype a invasive disease, Alaska, USA, 1983-2011. Emerg Infect Dis 2013;19:932-7
    • (2013) Emerg Infect Dis , vol.19 , pp. 932-937
    • Bruce, M.G.1    Zulz, T.2    DeByle, C.3
  • 39
  • 40
    • 84879234449 scopus 로고    scopus 로고
    • Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: Regional analysis and assessment of major determinants
    • e9
    • Griffiths UK, Clark A, Hajjeh R. Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants. J Pediatr 2013;163:S50-S9.e9
    • (2013) J Pediatr , vol.163 , pp. S50-S59
    • Griffiths, U.K.1    Clark, A.2    Hajjeh, R.3
  • 41
    • 3242797283 scopus 로고    scopus 로고
    • A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b
    • Vérez-Bencomo V, Fernández-Santana V, Ardí E, et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 2004;35:522
    • (2004) Science , vol.35 , pp. 522
    • Vérez-Bencomo, V.1    Fernández-Santana, V.2    Ardí, E.3
  • 42
    • 33749488093 scopus 로고    scopus 로고
    • Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against haemophilus influenzae type b in human adult volunteers
    • Torano G, Toledo ME, Baly A, et al. Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against haemophilus influenzae type b in human adult volunteers. Clin Vaccine Immunol 2006;13(9):1052-6
    • (2006) Clin Vaccine Immunol , vol.13 , Issue.9 , pp. 1052-1056
    • Torano, G.1    Toledo, M.E.2    Baly, A.3
  • 43
    • 84858769574 scopus 로고    scopus 로고
    • Evaluation of Haemophilus influenzae type b vaccine for routine immunization in Nepali infants
    • Metz JA, Hanieh S, Pradhan R, et al. Evaluation of Haemophilus influenzae type b vaccine for routine immunization in Nepali infants. Pediatr Infect Dis J 2012;31:e66-72
    • (2012) Pediatr Infect Dis J , vol.31 , pp. e66-e72
    • Metz, J.A.1    Hanieh, S.2    Pradhan, R.3
  • 44
    • 77953141751 scopus 로고    scopus 로고
    • The Elimination of Haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal
    • Cissé MF, Breugelmans JG, Bâ M, et al. The Elimination of Haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal. Pediatr Infect Dis J 2010;29:499-503
    • (2010) Pediatr Infect Dis J , vol.29 , pp. 499-503
    • Cissé, M.F.1    Breugelmans, J.G.2    Bâ, M.3
  • 45
    • 84879247307 scopus 로고    scopus 로고
    • Impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccination in India
    • Clark AD, Griffiths UK, Abbas SS, et al. Impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccination in India. J Pediatr 2013;163:S60-72
    • (2013) J Pediatr , vol.163 , pp. S60-S72
    • Clark, A.D.1    Griffiths, U.K.2    Abbas, S.S.3
  • 46
    • 22244476078 scopus 로고    scopus 로고
    • Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: A prospective study
    • Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005;366:144-50
    • (2005) Lancet , vol.366 , pp. 144-150
    • Adegbola, R.A.1    Secka, O.2    Lahai, G.3
  • 47
    • 84879197428 scopus 로고    scopus 로고
    • Incidence of Haemophilus influenzae type b disease in The Gambia 14 years after introduction of routine Haemophilus influenzae type b conjugate vaccine immunization
    • Oluwalana C, Howie SR, Secka O, et al. Incidence of Haemophilus influenzae type b disease in The Gambia 14 years after introduction of routine Haemophilus influenzae type b conjugate vaccine immunization. J Pediatr 2013;163:S4-7
    • (2013) J Pediatr , vol.163 , pp. S4-S7
    • Oluwalana, C.1    Howie, S.R.2    Secka, O.3
  • 48
    • 78649338859 scopus 로고    scopus 로고
    • Haemophilus influenzae type b conjugate vaccines: Considerations for vaccination schedules and implications for developing countries
    • Fitzwater SP, Watt JP, Levine OS, Santosham M. Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries. Hum Vaccin 2010;6:810-18
    • (2010) Hum Vaccin , vol.6 , pp. 810-818
    • Fitzwater, S.P.1    Watt, J.P.2    Levine, O.S.3    Santosham, M.4
  • 49
    • 78650837088 scopus 로고    scopus 로고
    • Continued control of pneumococcal disease in the UK - the impact of vaccination
    • Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Continued control of pneumococcal disease in the UK - the impact of vaccination. J Med Microbiol 2011;60:1-8
    • (2011) J Med Microbiol , vol.60 , pp. 1-8
    • Gladstone, R.A.1    Jefferies, J.M.2    Faust, S.N.3    Clarke, S.C.4
  • 50
    • 82455162581 scopus 로고    scopus 로고
    • Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model
    • Skinner JM, Indrawati L, Cannon J, et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 2011;29:8870-6
    • (2011) Vaccine , vol.29 , pp. 8870-8876
    • Skinner, J.M.1    Indrawati, L.2    Cannon, J.3
  • 51
    • 0033375209 scopus 로고    scopus 로고
    • A brief history of pneumococcal vaccines
    • Suppl 1
    • Austrian R. A brief history of pneumococcal vaccines. Drugs Aging 1999;15(Suppl 1):1-10
    • (1999) Drugs Aging , vol.15 , pp. 1-10
    • Austrian, R.1
  • 52
    • 84861480714 scopus 로고    scopus 로고
    • Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period
    • De Serres G, Pilishvili T, Link-Gelles R, et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine 2012;30:4067-72
    • (2012) Vaccine , vol.30 , pp. 4067-4072
    • De Serres, G.1    Pilishvili, T.2    Link-Gelles, R.3
  • 53
    • 71949103062 scopus 로고    scopus 로고
    • Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine
    • Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41
    • (2010) J Infect Dis , vol.201 , pp. 32-41
    • Pilishvili, T.1    Lexau, C.2    Farley, M.M.3
  • 54
    • 84882573112 scopus 로고    scopus 로고
    • Invasive Pneumococcal disease (IPD) in England and Wales after 7 -valent conjugate vaccine (PCV7); potential impact of 10 and 13 valent vaccines
    • Presented at the, 9 - 13 June, Brussels, Belgium
    • Kaye P, Malkani R, Martin S, et al. Invasive Pneumococcal Disease (IPD) in England and Wales after 7 -valent conjugate vaccine (PCV7); Potential impact of 10 and 13 valent vaccines. Presented at the 27th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID). 9 - 13 June 2009; Brussels, Belgium
    • (2009) 27th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID)
    • Kaye, P.1    Malkani, R.2    Martin, S.3
  • 55
    • 56349119400 scopus 로고    scopus 로고
    • The effect of vaccination on Streptococcus pneumoniae resistance
    • Leibovitz E. The effect of vaccination on Streptococcus pneumoniae resistance. Curr Infect Dis Rep 2008;10:182-91
    • (2008) Curr Infect Dis Rep , vol.10 , pp. 182-191
    • Leibovitz, E.1
  • 58
    • 84906679124 scopus 로고    scopus 로고
    • Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: Findings from cross-sectional carriage studies
    • Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health 2014;2:e397-405
    • (2014) Lancet Glob Health , vol.2 , pp. e397-e405
    • Hammitt, L.L.1    Akech, D.O.2    Morpeth, S.C.3
  • 59
    • 84884504627 scopus 로고    scopus 로고
    • Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes
    • Grant L, Burbidge P, Haston M, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One 2013;8(9):e74906
    • (2013) PLoS One , vol.8 , Issue.9
    • Grant, L.1    Burbidge, P.2    Haston, M.3
  • 60
    • 26944441984 scopus 로고    scopus 로고
    • Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae
    • Bieging KT, Rajam G, Holder P, et al. Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae. Clin Diagn Lab Immunol 2005;12:1238-42
    • (2005) Clin Diagn Lab Immunol , vol.12 , pp. 1238-1242
    • Bieging, K.T.1    Rajam, G.2    Holder, P.3
  • 61
    • 65549115895 scopus 로고    scopus 로고
    • Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine
    • Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28:S66-76
    • (2009) Pediatr Infect Dis J , vol.28 , pp. S66-S76
    • Vesikari, T.1    Wysocki, J.2    Chevallier, B.3
  • 62
    • 77649156773 scopus 로고    scopus 로고
    • Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?
    • Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010;10:4
    • (2010) BMC Pediatr , vol.10 , pp. 4
    • Hausdorff, W.P.1    Hoet, B.2    Schuerman, L.3
  • 63
    • 84903304920 scopus 로고    scopus 로고
    • Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial
    • Tregnaghi MW, Saéz-Llorens X, López P, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med 2014;11:e1001657
    • (2014) PLoS Med , vol.11
    • Tregnaghi, M.W.1    Saéz-Llorens, X.2    López, P.3
  • 64
    • 85099173020 scopus 로고    scopus 로고
    • Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiDCV10) against invasive pneumococcal disease: A cluster randomised trial
    • Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiDCV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013;381:214-22
    • (2013) Lancet , vol.381 , pp. 214-222
    • Palmu, A.A.1    Jokinen, J.2    Borys, D.3
  • 65
    • 33644645379 scopus 로고    scopus 로고
    • Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and nontypable Haemophilus influenzae: A randomised double-blind efficacy study
    • Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and nontypable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740-8
    • (2006) Lancet , vol.367 , pp. 740-748
    • Prymula, R.1    Peeters, P.2    Chrobok, V.3
  • 66
    • 70649103013 scopus 로고    scopus 로고
    • Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. Influenzae in children under 2 years of age
    • Prymula R, Kriz P, Kaliskova E, et al. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine 2009;28:71-8
    • (2009) Vaccine , vol.28 , pp. 71-78
    • Prymula, R.1    Kriz, P.2    Kaliskova, E.3
  • 69
    • 77956295617 scopus 로고    scopus 로고
    • Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers
    • Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010;126:e493-505
    • (2010) Pediatrics , vol.126 , pp. e493-e505
    • Yeh, S.H.1    Gurtman, A.2    Hurley, D.C.3
  • 70
    • 77953156443 scopus 로고    scopus 로고
    • Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers
    • Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010;17:1017-26
    • (2010) Clin Vaccine Immunol , vol.17 , pp. 1017-1026
    • Esposito, S.1    Tansey, S.2    Thompson, A.3
  • 71
    • 77951875521 scopus 로고    scopus 로고
    • Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine
    • Bryant KA, Block SL, Baker SA, Group PCVIS. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010;125:866-75
    • (2010) Pediatrics , vol.125 , pp. 866-875
    • Bryant, K.A.1    Block, S.L.2    Baker, S.A.3    Group, P.C.V.I.S.4
  • 72
    • 77952584765 scopus 로고    scopus 로고
    • Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany
    • Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010;28:4192-203
    • (2010) Vaccine , vol.28 , pp. 4192-4203
    • Kieninger, D.M.1    Kueper, K.2    Steul, K.3
  • 73
    • 84890085799 scopus 로고    scopus 로고
    • Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012
    • Demczuk WH, Martin I, Griffith A, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol 2013;59:778-88
    • (2013) Can J Microbiol , vol.59 , pp. 778-788
    • Demczuk, W.H.1    Martin, I.2    Griffith, A.3
  • 74
    • 85081860905 scopus 로고    scopus 로고
    • http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/BackgroundEpidemiologyPneumococcal/IPDGraphs/pneumoNumberLab-ConfirmedAgeSpecific/[Accessed 13 August 2014]
    • Public Health England. Numbers of laboratory confirmed invasive pneumococcal disease cases by age group, in England and Wales, 1996-2005. 2008. Available from: http://webarchive. nationalarchives.gov.uk/20140714084352/http://www.hpa.org. uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/BackgroundEpidemiologyPneumococcal/IPDGraphs/pneumoNumberLab-ConfirmedAgeSpecific/[Accessed 13 August 2014]
    • (2008) Numbers of Laboratory Confirmed Invasive Pneumococcal Disease Cases by Age Group, in England and Wales, 1996-2005
    • Public Health England1
  • 75
    • 78651230835 scopus 로고    scopus 로고
    • 13-valent pneumococcal conjugate vaccine
    • 9
    • 13-valent pneumococcal conjugate vaccine. Prescrire Int 2011;20(112):5-7; 9
    • (2011) Prescrire Int , vol.20 , Issue.112 , pp. 5-7
  • 76
    • 84885952880 scopus 로고    scopus 로고
    • Safety of 13-valent pneumococcal conjugate vaccine in infants and children: Meta-analysis of 13 clinical trials in 9 countries
    • Thompson A, Gurtman A, Patterson S, et al. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine 2013;31:5289-95
    • (2013) Vaccine , vol.31 , pp. 5289-5295
    • Thompson, A.1    Gurtman, A.2    Patterson, S.3
  • 77
    • 84896543826 scopus 로고    scopus 로고
    • Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults?
    • Weil-Olivier C, Gaillat J. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults? Vaccine 2014;32:2022-6
    • (2014) Vaccine , vol.32 , pp. 2022-2026
    • Weil-Olivier, C.1    Gaillat, J.2
  • 78
    • 84898449980 scopus 로고    scopus 로고
    • Pneumococcal vaccination strategies in adult population: Perspectives with the pneumococcal 13 -valent polysaccharide conjugate vaccine
    • Alicino C, Barberis I, Orsi A, Durando P. Pneumococcal vaccination strategies in adult population: perspectives with the pneumococcal 13 -valent polysaccharide conjugate vaccine. Minerva Med 2014;105:89-97
    • (2014) Minerva Med , vol.105 , pp. 89-97
    • Alicino, C.1    Barberis, I.2    Orsi, A.3    Durando, P.4
  • 79
    • 84880722937 scopus 로고    scopus 로고
    • Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
    • Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013;31:3577-84
    • (2013) Vaccine , vol.31 , pp. 3577-3584
    • Jackson, L.A.1    Gurtman, A.2    Van Cleeff, M.3
  • 80
    • 85081871825 scopus 로고    scopus 로고
    • Accessed 5 September 2014
    • FDA. PREVNAR 13 VRBPAC Adult Indication Briefing Document. 2011. Available from: http://www.fda. gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm279680.pdf [Accessed 5 September 2014]
    • (2011) PREVNAR 13 VRBPAC Adult Indication Briefing Document
    • FDA1
  • 81
    • 0035804857 scopus 로고    scopus 로고
    • Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era
    • Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001;285:1729-35
    • (2001) JAMA , vol.285 , pp. 1729-1735
    • Robinson, K.A.1    Baughman, W.2    Rothrock, G.3
  • 82
    • 67651097472 scopus 로고    scopus 로고
    • Invasive pneumococcal disease among adults: Associations among serotypes, disease characteristics, and outcome
    • Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009;49:e23-9
    • (2009) Clin Infect Dis , vol.49 , pp. e23-e29
    • Jansen, A.G.1    Rodenburg, G.D.2    Van Der Ende, A.3
  • 83
    • 84884220307 scopus 로고    scopus 로고
    • Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years
    • Mitchell R, Trück J, Pollard AJ. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years. Expert Opin Biol Ther 2013;13:1451-65
    • (2013) Expert Opin Biol Ther , vol.13 , pp. 1451-1465
    • Mitchell, R.1    Trück, J.2    Pollard, A.J.3
  • 84
    • 84892955220 scopus 로고    scopus 로고
    • 13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine
    • Frenck R, Thompson A, Senders S, et al. 13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2014;33:183-9
    • (2014) Pediatr Infect Dis J , vol.33 , pp. 183-189
    • Frenck, R.1    Thompson, A.2    Senders, S.3
  • 85
    • 78650215295 scopus 로고    scopus 로고
    • Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine -recommendations of the Advisory Committee on Immunization Practices (ACIP)
    • Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine -recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59:1-18
    • (2010) MMWR Recomm Rep , vol.59 , pp. 1-18
    • Centers for Disease Control and Prevention (CDC)1    Nuorti, J.P.2    Whitney, C.G.3
  • 86
    • 84861481752 scopus 로고    scopus 로고
    • The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
    • van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65:17-24
    • (2012) J Infect , vol.65 , pp. 17-24
    • Van Hoek, A.J.1    Andrews, N.2    Waight, P.A.3
  • 88
    • 84896544594 scopus 로고    scopus 로고
    • Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults aged 18-49 years, naïve to 23-valent pneumococcal polysaccharide vaccine
    • Presented at the, 27 - 30th April, Berlin
    • Bryant K, Frenck R, Gurtman A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults aged 18-49 years, naïve to 23-valent pneumococcal polysaccharide vaccine. Presented at the 23rd ECCMID (European Society of Clinical Microbiology and Infectious Diseases). 27 -- 30th April 2013; Berlin
    • (2013) 23rd ECCMID (European Society of Clinical Microbiology and Infectious Diseases)
    • Bryant, K.1    Frenck, R.2    Gurtman, A.3
  • 89
    • 77949332316 scopus 로고    scopus 로고
    • Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: Impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines
    • Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010;14:e197-209
    • (2010) Int J Infect Dis , vol.14 , pp. e197-e209
    • Isaacman, D.J.1    McIntosh, E.D.2    Reinert, R.R.3
  • 90
    • 84873262171 scopus 로고    scopus 로고
    • Imöhl M. Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children
    • van der Linden M, Reinert RR, Kern WV, Imöhl M. Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children. BMC Infect Dis 2013;13:70
    • (2013) BMC Infect Dis , vol.13 , pp. 70
    • Van Der Linden, M.1    Reinert, R.R.2    Kern, W.V.3
  • 91
    • 84862198729 scopus 로고    scopus 로고
    • Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
    • Earnshaw SR, McDade CL, Zanotti G, et al. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis 2012;12:101
    • (2012) BMC Infect Dis , vol.12 , pp. 101
    • Earnshaw, S.R.1    McDade, C.L.2    Zanotti, G.3
  • 92
    • 84883169333 scopus 로고    scopus 로고
    • A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries
    • Martí SG, Colantonio L, Bardach A, et al. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc 2013;11:21
    • (2013) Cost Eff Resour Alloc , vol.11 , pp. 21
    • Martí, S.G.1    Colantonio, L.2    Bardach, A.3
  • 93
    • 78650497300 scopus 로고    scopus 로고
    • Global prevailing and emerging pediatric pneumococcal serotypes
    • McIntosh ED, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines 2011;10:109-29.
    • (2011) Expert Rev Vaccines , vol.10 , pp. 109-129
    • McIntosh, E.D.1    Reinert, R.R.2
  • 94
    • 80051938182 scopus 로고    scopus 로고
    • New conjugate vaccines for the prevention of pneumococcal disease in developing countries
    • Ginsburg AS, Alderson MR. New conjugate vaccines for the prevention of pneumococcal disease in developing countries. Drugs Today 2011;47(3):207-14
    • (2011) Drugs Today , vol.47 , Issue.3 , pp. 207-214
    • Ginsburg, A.S.1    Alderson, M.R.2
  • 95
    • 34249930262 scopus 로고    scopus 로고
    • Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP
    • Cao J, Chen D, Xu W, et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Vaccine 2007;25:4996-5005
    • (2007) Vaccine , vol.25 , pp. 4996-5005
    • Cao, J.1    Chen, D.2    Xu, W.3
  • 96
    • 61849117441 scopus 로고    scopus 로고
    • Caseinolytic protease: A protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection
    • Cao J, Li D, Gong Y, et al. Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection. Clin Exp Immunol 2009;156:52-60.
    • (2009) Clin Exp Immunol , vol.156 , pp. 52-60
    • Cao, J.1    Li, D.2    Gong, Y.3
  • 97
    • 84899994434 scopus 로고    scopus 로고
    • Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial
    • Prymula R, Pazdiora P, Traskine M, et al. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial. Vaccine 2014;32:3025-34.
    • (2014) Vaccine , vol.32 , pp. 3025-3034
    • Prymula, R.1    Pazdiora, P.2    Traskine, M.3
  • 98
    • 78149387943 scopus 로고    scopus 로고
    • Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: The pneumococcal global serotype project
    • Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010;7
    • (2010) PLoS Med , pp. 7
    • Johnson, H.L.1    Deloria-Knoll, M.2    Levine, O.S.3
  • 99
    • 79953132642 scopus 로고    scopus 로고
    • The African vaccine-preventable diseases network: A vaccine advocacy initiative
    • Wiysonge CS, Armah GE, Madhi SA, et al. The African Vaccine-Preventable Diseases Network: a vaccine advocacy initiative. Pan Afr Med J 2011;8:24
    • (2011) Pan Afr Med J , vol.8 , pp. 24
    • Wiysonge, C.S.1    Armah, G.E.2    Madhi, S.A.3
  • 100
    • 67349129949 scopus 로고    scopus 로고
    • Accessed 4 September 2014
    • UNICEF/WHO. Expanding immunization coverage. 2011. Available from: http://www.unicef.org/immunization/index-coverage.html [Accessed 4 September 2014]
    • (2011) Expanding Immunization Coverage
    • UNICEF/WHO1
  • 102
    • 84873255900 scopus 로고    scopus 로고
    • Accessed 3 July 2014
    • HealthyPeople.gov. Immunization and Infectious Diseases. 2014. Available from: http://www. healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=23 [Accessed 3 July 2014]
    • (2014) Immunization and Infectious Diseases
  • 103
    • 84888098943 scopus 로고    scopus 로고
    • Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X
    • Micoli F, Romano MR, Tontini M, et al. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci USA 2013;110:19077-82
    • (2013) Proc Natl Acad Sci USA , vol.110 , pp. 19077-19082
    • Micoli, F.1    Romano, M.R.2    Tontini, M.3
  • 104
    • 84883598147 scopus 로고    scopus 로고
    • Effectiveness of meningococcal serogroup C vaccine programmes
    • Borrow R, Abad R, Trotter C, et al. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine 2013;31:4477-86.
    • (2013) Vaccine , vol.31 , pp. 4477-4486
    • Borrow, R.1    Abad, R.2    Trotter, C.3
  • 105
    • 84874708395 scopus 로고    scopus 로고
    • The changing epidemiology of meningococcal disease in North America 1945-2010
    • Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccin Immunother 2013;9:162-71
    • (2013) Hum Vaccin Immunother , vol.9 , pp. 162-171
    • Baccarini, C.1    Ternouth, A.2    Wieffer, H.3    Vyse, A.4
  • 106
    • 84872232701 scopus 로고    scopus 로고
    • Meningococcal serogroup Y emergence in Europe: Update 2011
    • Br€oker M, Jacobsson S, Kuusi M, et al. Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother 2012;8:1907-11
    • (2012) Hum Vaccin Immunother
    • Bröker, M.1    Jacobsson, S.2    Kuusi, M.3
  • 108
    • 0035888124 scopus 로고    scopus 로고
    • Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story
    • Suppl 1
    • Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20(Suppl 1):S58-67
    • (2001) Vaccine , vol.20 , pp. S58-S67
    • Miller, E.1    Salisbury, D.2    Ramsay, M.3
  • 109
    • 0035915614 scopus 로고    scopus 로고
    • Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
    • Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001;357:195-6
    • (2001) Lancet , vol.357 , pp. 195-196
    • Ramsay, M.E.1    Andrews, N.2    Kaczmarski, E.B.3    Miller, E.4
  • 111
    • 3242768475 scopus 로고    scopus 로고
    • Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
    • Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365-7
    • (2004) Lancet , vol.364 , pp. 365-367
    • Trotter, C.L.1    Andrews, N.J.2    Kaczmarski, E.B.3
  • 112
    • 20444437173 scopus 로고    scopus 로고
    • Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain
    • Larrauri A, Cano R, Garciá M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005;23:4097-100
    • (2005) Vaccine , vol.23 , pp. 4097-4100
    • Larrauri, A.1    Cano, R.2    Garciá, M.3    Mateo, S.4
  • 113
    • 33746653839 scopus 로고    scopus 로고
    • Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules
    • Cameron C, Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro Surveill 2006;11:E060302.4
    • (2006) Euro Surveill , vol.11
    • Cameron, C.1    Pebody, R.2
  • 114
    • 77952004260 scopus 로고    scopus 로고
    • Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: Effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity
    • Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17:840-7
    • (2010) Clin Vaccine Immunol , vol.17 , pp. 840-847
    • Campbell, H.1    Andrews, N.2    Borrow, R.3
  • 115
    • 84861526415 scopus 로고    scopus 로고
    • Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom
    • Findlow H, Borrow R, Andrews N, et al. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom. Pediatr Infect Dis J 2012;31:616-22
    • (2012) Pediatr Infect Dis J , vol.31 , pp. 616-622
    • Findlow, H.1    Borrow, R.2    Andrews, N.3
  • 116
    • 33751555760 scopus 로고    scopus 로고
    • Serogroup C meningococcal glycoconjugate vaccine in adolescents: Persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
    • Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006;43:1387-94.
    • (2006) Clin Infect Dis , vol.43 , pp. 1387-1394
    • Snape, M.D.1    Kelly, D.F.2    Salt, P.3
  • 117
    • 0036677184 scopus 로고    scopus 로고
    • Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children
    • McVernon J, Maclennan J, Buttery J, et al. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J 2002;21:747-53
    • (2002) Pediatr Infect Dis J , vol.21 , pp. 747-753
    • McVernon, J.1    Maclennan, J.2    Buttery, J.3
  • 118
    • 47149093375 scopus 로고    scopus 로고
    • Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: Observational study
    • Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008;336:1487-91
    • (2008) BMJ , vol.336 , pp. 1487-1491
    • Snape, M.D.1    Kelly, D.F.2    Lewis, S.3
  • 119
    • 77952993552 scopus 로고    scopus 로고
    • Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: A phase 4 clinical trial
    • Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 2010;50(12):1601-10
    • (2010) Clin Infect Dis , vol.50 , Issue.12 , pp. 1601-1610
    • Perrett, K.P.1    Winter, A.P.2    Kibwana, E.3
  • 121
    • 84883133746 scopus 로고    scopus 로고
    • Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
    • de Whalley PC, Snape MD, Plested E, et al. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Arch Dis Child 2013;98:686-91
    • (2013) Arch Dis Child , vol.98 , pp. 686-691
    • De Whalley, P.C.1    Snape, M.D.2    Plested, E.3
  • 122
    • 84903515497 scopus 로고    scopus 로고
    • Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers
    • Stoof SP, van der Klis FR, van Rooijen DM, et al. Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers. PLoS One 2014;9:e100651
    • (2014) PLoS One , vol.9
    • Stoof, S.P.1    Van Der Klis, F.R.2    Van Rooijen, D.M.3
  • 125
    • 83155176172 scopus 로고    scopus 로고
    • Meningococcal conjugate vaccines policy update: Booster dose recommendations
    • Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. Pediatrics 2011;128(6):1213-18
    • (2011) Pediatrics , vol.128 , Issue.6 , pp. 1213-1218
    • Committee on Infectious Diseases1
  • 127
    • 0031552196 scopus 로고    scopus 로고
    • Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales
    • Ramsay M, Kaczmarski E, Rush M, et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev 1997;7:R49-54
    • (1997) Commun Dis Rep CDR Rev , vol.7 , pp. R49-R54
    • Ramsay, M.1    Kaczmarski, E.2    Rush, M.3
  • 128
    • 40549089883 scopus 로고    scopus 로고
    • Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity
    • Maiden MC, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-43
    • (2008) J Infect Dis , vol.197 , pp. 737-743
    • Maiden, M.C.1    Ibarz-Pavón, A.B.2    Urwin, R.3
  • 129
    • 73649112805 scopus 로고    scopus 로고
    • Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: Implications for prevention of meningococcal disease
    • Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010;50:184-91.
    • (2010) Clin Infect Dis , vol.50 , pp. 184-191
    • Cohn, A.C.1    MacNeil, J.R.2    Harrison, L.H.3
  • 131
    • 79957886417 scopus 로고    scopus 로고
    • Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants
    • Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics 2011;127:e1375-85.
    • (2011) Pediatrics , vol.127 , pp. e1375-e1385
    • Bryant, K.A.1    Marshall, G.S.2    Marchant, C.D.3
  • 132
    • 74049124340 scopus 로고    scopus 로고
    • Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants
    • Marchant CD, Miller JM, Marshall GS, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010;29:48-52.
    • (2010) Pediatr Infect Dis J , vol.29 , pp. 48-52
    • Marchant, C.D.1    Miller, J.M.2    Marshall, G.S.3
  • 133
    • 77952118055 scopus 로고    scopus 로고
    • Accessed 17 November 2014
    • Nimenrix. Summary of product characteristics. Available from: http://www.medicines.org.uk/emc/medicine/26514 [Accessed 17 November 2014]
    • Summary of Product Characteristics
    • Nimenrix1
  • 134
    • 79956193785 scopus 로고    scopus 로고
    • An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-monthold children
    • Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-monthold children. Vaccine 2011;29:4264-73.
    • (2011) Vaccine , vol.29 , pp. 4264-4273
    • Knuf, M.1    Pantazi-Chatzikonstantinou, A.2    Pfletschinger, U.3
  • 135
    • 84874465958 scopus 로고    scopus 로고
    • Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: Results of an open, randomised, controlled study
    • Borja-Tabora C, Montalban C, Memish ZA, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis 2013;13:116
    • (2013) BMC Infect Dis , vol.13 , pp. 116
    • Borja-Tabora, C.1    Montalban, C.2    Memish, Z.A.3
  • 136
    • 84876665145 scopus 로고    scopus 로고
    • Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2- 10-year-old children: Results of an open, randomised, controlled study
    • Knuf M, Romain O, Kindler K, et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2- 10-year-old children: results of an open, randomised, controlled study. Eur J Pediatr 2013;172:601-12
    • (2013) Eur J Pediatr , vol.172 , pp. 601-612
    • Knuf, M.1    Romain, O.2    Kindler, K.3
  • 137
    • 84874494263 scopus 로고    scopus 로고
    • Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)
    • Østergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis 2013;17:e173-6.
    • (2013) Int J Infect Dis , vol.17 , pp. e173-e176
    • Østergaard, L.1    Van Der Wielen, M.2    Bianco, V.3    Miller, J.M.4
  • 138
    • 84898483961 scopus 로고    scopus 로고
    • Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: A new conjugate vaccine against invasive meningococcal disease
    • Hedari C, Khinkarly RW, Dbaibo GS. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect Drug Resist 2014;7:85-99
    • (2014) Infect Drug Resist , vol.7 , pp. 85-99
    • Hedari, C.1    Khinkarly, R.W.2    Dbaibo, G.S.3
  • 139
    • 84872282456 scopus 로고    scopus 로고
    • Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity
    • Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013;56:354-63
    • (2013) Clin Infect Dis , vol.56 , pp. 354-363
    • Kristiansen, P.A.1    Diomandé, F.2    Ba, A.K.3
  • 140
    • 84880934608 scopus 로고    scopus 로고
    • Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine
    • Kristiansen PA, Ba AK, Sanou I, et al. Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine. BMC Infect Dis 2013;13:363
    • (2013) BMC Infect Dis , vol.13 , pp. 363
    • Kristiansen, P.A.1    Ba, A.K.2    Sanou, I.3
  • 141
    • 79959305905 scopus 로고    scopus 로고
    • Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans
    • Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011;364:2293-304
    • (2011) N Engl J Med , vol.364 , pp. 2293-2304
    • Sow, S.O.1    Okoko, B.J.2    Diallo, A.3
  • 142
    • 84896726517 scopus 로고    scopus 로고
    • Benefits of using vaccines out of the cold chain: Delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin
    • Zipursky S, Djingarey MH, Lodjo JC, et al. Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin. Vaccine 2014;32:1431-5.
    • (2014) Vaccine , vol.32 , pp. 1431-1435
    • Zipursky, S.1    Djingarey, M.H.2    Lodjo, J.C.3
  • 144
    • 84889032744 scopus 로고    scopus 로고
    • Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination
    • Collard JM, Issaka B, Zaneidou M, et al. Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect Dis 2013;13:576
    • (2013) BMC Infect Dis , vol.13 , pp. 576
    • Collard, J.M.1    Issaka, B.2    Zaneidou, M.3
  • 145
    • 0035196375 scopus 로고    scopus 로고
    • Clonal expansion of sequence type (ST-) 5 and emergence of ST-7 in serogroup A meningococci, Africa
    • Nicolas P, Décousset L, Riglet V, et al. Clonal expansion of sequence type (ST-) 5 and emergence of ST-7 in serogroup A meningococci, Africa. Emerg Infect Dis 2001;7:849-54
    • (2001) Emerg Infect Dis , vol.7 , pp. 849-854
    • Nicolas, P.1    Décousset, L.2    Riglet, V.3
  • 146
    • 26944439440 scopus 로고    scopus 로고
    • Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes
    • Nicolas P, Norheim G, Garnotel E, et al. Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005;43:5129-35
    • (2005) J Clin Microbiol , vol.43 , pp. 5129-5135
    • Nicolas, P.1    Norheim, G.2    Garnotel, E.3
  • 147
    • 79956323880 scopus 로고    scopus 로고
    • Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso
    • Article describing the epidemic potential of meningococcal serogroup X.
    • Delrieu I, Yaro S, Tamekloé TA, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011;6:e19513 . Article describing the epidemic potential of meningococcal serogroup X.
    • (2011) PLoS One , vol.6
    • Delrieu, I.1    Yaro, S.2    Tamekloé, T.A.3
  • 149
    • 84903304241 scopus 로고    scopus 로고
    • Improving access to vaccines through tiered pricing
    • Berkley S. Improving access to vaccines through tiered pricing. Lancet 2014;383:2265-7
    • (2014) Lancet , vol.383 , pp. 2265-2267
    • Berkley, S.1
  • 150
    • 85081862485 scopus 로고    scopus 로고
    • Accessed 30 August 2014
    • UNICEF. Ukraine Statistics. 2013. Available from: http://www.unicef. org/infobycountry/ukraine-statistics.html [Accessed 30 August 2014]
    • (2013) Ukraine Statistics
    • UNICEF1
  • 151
    • 85081865921 scopus 로고    scopus 로고
    • Accessed 4 September 2014
    • UNICEF. Egypt Statistics. 2013. Available from: http://www.unicef. org/infobycountry/egypt-statistics.html [Accessed 4 September 2014]
    • (2013) Egypt Statistics
    • UNICEF1
  • 152
    • 85081870951 scopus 로고    scopus 로고
    • Accessed 4 September 2014
    • UNICEF. Syria Statistics. 2013. Available from: http://www.unicef. org/infobycountry/syria-statistics.html [Accessed 4 September 2014]
    • (2013) Syria Statistics
    • UNICEF1
  • 154
    • 85081863887 scopus 로고    scopus 로고
    • Accessed 4 September 2014
    • The Lancet Infectious Diseases. A wakeup call for polio eradication 2014. Available from: http://www.thelancet. com/journals/laninf/article/PIIS1473-3099(13)70368-2/fulltext%3Felsca1%3DETOC-TLID%26elsca2%3Demail%26elsca3%3DHTDJ [Accessed 4 September 2014]
    • (2014) A Wakeup Call for Polio Eradication
    • The Lancet Infectious Diseases1
  • 155
    • 84878995680 scopus 로고    scopus 로고
    • CD4+ T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens
    • Sharma SK, Roumanes D, Almudevar A, et al. CD4+ T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens. Vaccine 2013;31:3090-7
    • (2013) Vaccine , vol.31 , pp. 3090-3097
    • Sharma, S.K.1    Roumanes, D.2    Almudevar, A.3
  • 156
    • 33645532223 scopus 로고    scopus 로고
    • Pneumococcal vaccine-direct and indirect ("herd") effects
    • Musher DM. Pneumococcal vaccine--direct and indirect ("herd") effects. N Engl J Med 2006;354:1522-4
    • (2006) N Engl J Med , vol.354 , pp. 1522-1524
    • Musher, D.M.1
  • 157
    • 34547948567 scopus 로고    scopus 로고
    • Capsule switching and capsule replacement in vaccine-preventable bacterial diseases
    • Tsang R. Capsule switching and capsule replacement in vaccine-preventable bacterial diseases. Lancet Infect Dis 2007;7:569-70
    • (2007) Lancet Infect Dis , vol.7 , pp. 569-570
    • Tsang, R.1
  • 158
    • 33748883185 scopus 로고    scopus 로고
    • No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales
    • author reply 7-8
    • Trotter CL, Ramsay ME, Gray S, et al. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 2006;6:616-17; author reply 7-8
    • (2006) Lancet Infect Dis , vol.6 , pp. 616-617
    • Trotter, C.L.1    Ramsay, M.E.2    Gray, S.3
  • 159
    • 20844442319 scopus 로고    scopus 로고
    • Capsules, clones, and curious events: Pneumococcus under fire from polysaccharide conjugate vaccine
    • Long SS. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin Infect Dis 2005;41:30-4
    • (2005) Clin Infect Dis , vol.41 , pp. 30-34
    • Long, S.S.1
  • 160
    • 84889680691 scopus 로고    scopus 로고
    • Advances towards the prevention of meningococcal B disease: A multidimensional story
    • Suppl 1
    • Roderick M, Finn A. Advances towards the prevention of meningococcal B disease: a multidimensional story. J Infect 2014;68(Suppl 1):S76-82
    • (2014) J Infect , vol.68 , pp. S76-S82
    • Roderick, M.1    Finn, A.2
  • 161
    • 33845600413 scopus 로고    scopus 로고
    • WHO vaccine-preventable diseases: Monitoring system
    • Accessed 4 September 2014
    • World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2014 global summary. 2014. Available from: http://apps.who. int/immunization-monitoring/globalsummary [Accessed 4 September 2014]
    • (2014) 2014 Global Summary
    • World Health Organization1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.